Clinical Trial Update: Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

View source ↗

Summary

Clinical trial update reporting outcomes of Lotemax 0.5% for ocular inflammation after cataract surgery in pseudophakia patients; results posted after completio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation
• Pseudophakia

Drugs mentioned

• Lotemax 0.5% (loteprednol etabonate)

Snippet

Sponsor: Toyos Clinic | Conditions: Pseudophakia, Inflammation | Status: COMPLETED | Results posted: 2018-10-22